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Abstract
A recent paper by Grutters et al makes the case for early health economic modeling in the development of health 
technologies. A number of examples of the value of early modeling are given, with analyses being performed at 
different stages in the development of several non-drug health technologies. This commentary acknowledges 
the contribution of the paper by Grutters et al and argues for an iterative and integrated approach to early 
modeling, assessing the cost-effectiveness of the technology, the value of future research and the interaction 
with the manufacturer’s pricing and revenue expectations.
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Introduction
In their recent paper, Grutters et al1 discuss the role of early 
health economic modeling in making key decisions in the 
development of health technologies. Their observations are 
based on 32 early modeling analyses of non-drug technologies 
undertaken by a subsidiary group of a university hospital in 
the Netherlands. The analyses were all conducted as a result 
of requests from technology sponsors, the majority of which 
were medical devices companies, although 3 analyses were 
conducted following requests by clinicians and/or clinical 
departments from the hospital. 
The modeling analyses were performed at different stages 
in the development of the technologies, from ‘idea screening,’ 
through ‘concept development,’ to the ‘pre-market phase’ to 
‘market access.’ The authors note that some researchers may 
not consider the final phase to constitute ‘early modeling,’ but 
I accept their view that this stage still precedes any formal 
modeling presented to authorities in an official reimbursement 
submission. The main finding is that none of the assessments 
resulted in a firm ‘go/no-go’ decision about the technologies 
concerned, since none demonstrated that the technology 
could never be cost-effective. However, the assessments were 
helpful in gaining an insight into the technology’s potential 
cost-effectiveness in its intended context by informing further 
development or implementation. These insights could include 
the positioning of the technology (eg, position in the clinical 
pathway, or suitability for different patient sub-groups), or the 
need for additional research.
Therefore, there are two, interlinked, modeling efforts that 
could be performed. The first is the modeling of the potential 
cost-effectiveness of the product, viewed from the perspective 
of the external decision-maker(s) that will partly determine 
the market access for the technology. The second is a financial 
modeling effort, from the perspective of the company, to 
assess whether the potential financial returns will justify the 
investments in developing the product.
Value of the Grutters et al Study
The main value of the study by Grutter et al is that, since the 
analyses were performed by an independent organization, 
the findings could be placed in the public domain, following 
some restrictions to preserve confidential findings on the 
technologies concerned. This is important, since although 
much has been written about the potential value of early health 
economic modeling, there are few published examples of its 
impact or value. This is because the vast majority of analyses 
have been conducted in-house by technology manufacturers 
(mainly pharmaceutical companies), where there is little 
need or incentive to make them public. The closest we see to 
actual examples relate to the preparatory work conducted by 
manufacturers to support ‘early engagement’ discussions with 
regulators and reimbursement authorities.2
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Issues for Further Discussion
Although the paper by Grutters et al makes a strong case for 
the role of early health economic modeling, there are other 
issues meriting discussion, should we wish to assess how 
useful early modeling could be. The first issue relates to the 
question of go/no-go decisions. It is correct to argue that if all 
the assessments conclude that a technology is cost-effective, 
it is hard to argue that it should be abandoned. But it is not 
clear how the assessments undertaken considered the price 
(or acquisition cost) of the technologies concerned. Some of 
the analyses conducted close to market access presumably 
included a price, but it is not clear whether the analyses 
conducted in earlier stages of development accounted for 
the manufacturer’s price expectations, or if any were even 
articulated. In the absence of inclusion of any price, or if price 
was varied in a sensitivity analysis, the modeling could still 
give the manufacturer an indication of whether particular 
price expectations could be met. 
The point is that, whatever the benefits in improved 
health and cost savings, any technology could be rejected on 
grounds of lacking cost-effectiveness if the manufacturer’s 
price expectations were too high. Ideally, the manufacturer’s 
price expectations would be set early on and revised upwards 
or downwards as more information about the technology’s 
performance, or the need for additional research, becomes 
known. However, in most cases, decisions about price are 
usually discussed quite late in the development process, when 
arguably the decision might mainly be based on recovery of 
as many of the research and development costs as possible, 
rather than the level of profit that the technology is likely to 
make overall. Therefore, in order to best interpret the results 
of modeling, price expectations should be set earlier and reset 
periodically based on the acquisition of new information.
Secondly, as Grutters et al note, early health economic 
modeling can be useful in guiding future research into the 
technology concerned. This is often because of the need to 
obtain more accurate estimates of the key parameters of the 
model, but could also be because the model indicates that 
there may be benefits from studying the technology in new 
patient populations or at a different position in the treatment 
pathway.
Grutters et al are a little sceptical about whether probabilistic 
sensitivity analysis is the best way of characterizing 
uncertainty in situations where the quality of the information 
about the new technology is poor. Rather, they favour the 
use of deterministic sensitivity analysis. There is debate 
about this issue in the health economics literature, although 
one of the arguments in favour of a probabilistic approach is 
that it facilitates the use of formal value of information (VoI) 
analysis to guide future research. For example, VoI analysis 
can provide an estimate of the overall value of conducting 
more research to reduce decision uncertainty. It can also 
identify which model parameters it would most important to 
estimate more precisely. In addition, as Rothery et al3 point 
out, VoI analysis provides the manufacturer with a formal 
approach for considering the trade-off, at different stages 
of development, between carrying out further research and 
revising price expectations for the technology downwards. 
This links back to the point about pricing expectations made 
earlier.
Thirdly, one of the interesting features of the paper 
by Grutters et al is that it demonstrates that early health 
economic modeling can be performed at different time points 
in the development of a technology. In the paper, the time 
points were determined by the timing of the requests for 
analyses by the technology’s sponsor. In two cases the analysis 
was performed twice, although it is not clear whether this was 
at different time points or not. However, in principle, early 
stage health economic modeling is not a ‘one-time’ activity, 
but should be continuous and iterative, with the modeling 
being updated as more information becomes available, either 
about the technology itself or the environment in which it 
would be used (eg, emergence of new technologies, changes 
in prices, etc).4 
For example, the price of the existing technology, that the 
manufacturer’s technology seeks to replace, could fall, making 
the new technology less attractive. This happened with drug-
eluting stents in the United Kingdom. The price of bare 
metal stents fell, causing the incremental cost-effectiveness 
of drug-eluting stents to rise above the acceptable threshold 
in the United Kingdom.5 Alternatively, a new competitor 
technology could emerge, or there could be a change in 
decision-makers’ requirements for evidence on effectiveness 
or cost-effectiveness.
Towards a Comprehensive Role for Early Stage Modeling
Grutters et al should be congratulated on an important 
contribution to the debate about the value of early health 
economic modeling. Based on their findings and the issues 
raised above, one could argue for a more comprehensive role 
for early stage health economic modeling. First, it would 
be iterative, with modeling being performed at multiple 
points in the development of the technology, normally at 
key points where either (i) an important decisions about 
the need for further research, or a change in positioning or 
pricing expectations needed to be made, or (ii) there was an 
important change in the external environment affecting the 
likely success or value of the technology.
Secondly, the modeling effort would comprise three, 
interlinked efforts (i) cost-effectiveness modeling from 
the perspective of the intended payer or reimbursement 
authority; (ii) modeling of the future research strategy for the 
technology, based on VoI analysis where possible; and (iii) 
financial modeling, of expected research costs, technology 
price and revenue, from the perspective of the manufacturer. 
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